| pubmed-article:19679378 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19679378 | lifeskim:mentions | umls-concept:C0220781 | lld:lifeskim |
| pubmed-article:19679378 | lifeskim:mentions | umls-concept:C0220825 | lld:lifeskim |
| pubmed-article:19679378 | lifeskim:mentions | umls-concept:C1441547 | lld:lifeskim |
| pubmed-article:19679378 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:19679378 | lifeskim:mentions | umls-concept:C0450442 | lld:lifeskim |
| pubmed-article:19679378 | lifeskim:mentions | umls-concept:C0439596 | lld:lifeskim |
| pubmed-article:19679378 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:19679378 | pubmed:dateCreated | 2009-10-9 | lld:pubmed |
| pubmed-article:19679378 | pubmed:abstractText | As part of an ongoing effort to develop highly potent anti-tuberculosis agents, fourteen pentacyclo-undecane (PCU) tetra-amine compounds were synthesized and screened for their in vitro anti-mycobacterial activity against two TB strains, H37Rv and XDR 194 [an extensively drug-resistant strain of tuberculosis]. Using the broth macrodilution method, nitrofuranylamide based compounds (6a and 6b) showed almost similar activities against the H37Rv strain of Mycobacterium tuberculosis when compared with the control drug, ethambutol. N-Geranyl piperazine PCU (8a) and trans-trans farnesyl piperazine PCU (8b) were 3.2 and 3.7 times more potent than commercially available ethambutol. Both isoprenyl PCU tetra-amine derivatives and N-decyl piperazine PCU (9a) were highly active against the XDR 194 strain of tuberculosis with MICs in the range of 0.63-3.02 microM. Cytotoxicities (IC(50)) of isoprenyl based compounds (8a, 8b) and compound 9a were tested on a mammalian cell line [MDBK (Madin Darby bovine kidney epithelium)] with values of 30, 24 and 25 microM respectively. | lld:pubmed |
| pubmed-article:19679378 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19679378 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19679378 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19679378 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19679378 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19679378 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19679378 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19679378 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:19679378 | pubmed:issn | 1768-3254 | lld:pubmed |
| pubmed-article:19679378 | pubmed:author | pubmed-author:VongB GBG | lld:pubmed |
| pubmed-article:19679378 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:19679378 | pubmed:author | pubmed-author:KrugerHendrik... | lld:pubmed |
| pubmed-article:19679378 | pubmed:author | pubmed-author:GovenderThave... | lld:pubmed |
| pubmed-article:19679378 | pubmed:author | pubmed-author:PillayManormo... | lld:pubmed |
| pubmed-article:19679378 | pubmed:author | pubmed-author:GovenderPatri... | lld:pubmed |
| pubmed-article:19679378 | pubmed:author | pubmed-author:OnajoleOlusey... | lld:pubmed |
| pubmed-article:19679378 | pubmed:author | pubmed-author:MaguireGlenn... | lld:pubmed |
| pubmed-article:19679378 | pubmed:author | pubmed-author:GovenderKarni... | lld:pubmed |
| pubmed-article:19679378 | pubmed:author | pubmed-author:MuthusamyKare... | lld:pubmed |
| pubmed-article:19679378 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19679378 | pubmed:volume | 44 | lld:pubmed |
| pubmed-article:19679378 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19679378 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19679378 | pubmed:pagination | 4297-305 | lld:pubmed |
| pubmed-article:19679378 | pubmed:meshHeading | pubmed-meshheading:19679378... | lld:pubmed |
| pubmed-article:19679378 | pubmed:meshHeading | pubmed-meshheading:19679378... | lld:pubmed |
| pubmed-article:19679378 | pubmed:meshHeading | pubmed-meshheading:19679378... | lld:pubmed |
| pubmed-article:19679378 | pubmed:meshHeading | pubmed-meshheading:19679378... | lld:pubmed |
| pubmed-article:19679378 | pubmed:meshHeading | pubmed-meshheading:19679378... | lld:pubmed |
| pubmed-article:19679378 | pubmed:meshHeading | pubmed-meshheading:19679378... | lld:pubmed |
| pubmed-article:19679378 | pubmed:meshHeading | pubmed-meshheading:19679378... | lld:pubmed |
| pubmed-article:19679378 | pubmed:meshHeading | pubmed-meshheading:19679378... | lld:pubmed |
| pubmed-article:19679378 | pubmed:meshHeading | pubmed-meshheading:19679378... | lld:pubmed |
| pubmed-article:19679378 | pubmed:meshHeading | pubmed-meshheading:19679378... | lld:pubmed |
| pubmed-article:19679378 | pubmed:meshHeading | pubmed-meshheading:19679378... | lld:pubmed |
| pubmed-article:19679378 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19679378 | pubmed:articleTitle | Pentacyclo-undecane derived cyclic tetra-amines: synthesis and evaluation as potent anti-tuberculosis agents. | lld:pubmed |
| pubmed-article:19679378 | pubmed:affiliation | School of Chemistry, University of KwaZulu-Natal, Durban, South Africa. | lld:pubmed |
| pubmed-article:19679378 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19679378 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:19679378 | lld:chembl |
